iECURE Launches With $50 Million Series A Financing to Develop In Vivo Gene Insertion Approaches for Devastating Diseases

10 Sep, 2021

iECURE Launches With $50 Million Series A Financing to Develop In Vivo Gene Insertion Approaches for Devastating Diseases
Photo by ThisisEngineering RAEng on Unsplash

– iECURE (pronounced EE-ah-cure), a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need, announced it has closed a $50m Series A financing led by Versant Ventures and OrbiMed Advisors.
– The funds will be used to advance iECURE’s pipeline of up to 13 programs, all of which benefit from gene editing and in vivo delivery approaches being developed in the laboratory of James Wilson, M.D., Ph.D., of the University of Pennsylvania Gene Therapy Program (GTP).
– iECURE’s approach focuses on the mutation-agnostic in vivo insertion of healthy copies of disease-causing genes, with an initial focus in liver disorders.

Health North America
Crunchbase icon

Content report

The following text will be sent to our editors: